Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 3/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200471 | 0.83 | NOTUM (0.42) | P2RX7MAPK1 | |
| SCHEMBL9702588 | 0.82 | ALPL (0.32) | AHRALPLCES1 | |
| SCHEMBL5815364 | 0.76 | ALDH1A1 (0.49) | CES1 | |
| SCHEMBL705941 | 0.76 | HSD11B1 (0.44) | AHRALPL | |
| Pyridine SCHEMBL5816669 | 0.75 | P2RX7 (0.41) | P2RX7MAPK1 | |
| SCHEMBL30629345 | 0.74 | DCUN1D1 (0.47) | ALPLCYP3A4 | |
| SCHEMBL1774388 | 0.74 | DCUN1D1 (0.47) | ALPLCYP3A4 | |
| SCHEMBL24690273 | 0.73 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL5814079 | 0.73 | TNF (0.30) | — | |
| SCHEMBL2158308 | 0.73 | CYP3A4 (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | AHR 868/4885ALPL 4674/4885P2RX7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.